MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Yehuda R, Hoge CW, McFarlane AC, Vermetten E, Lanius RA, Nievergelt CM, et al. Post-traumatic stress disorder. Nat Rev Dis Prim. 2015;1:15057.

  2. 2.

    Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019;236:2735–45.

  3. 3.

    De la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of MDMA “exstasy” in humans. Br J Clin Pharm. 2000;49:104–9.

  4. 4.

    Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019;569:116.6.

  5. 5.

    Wagner AC, Mithoefer MC, Mithoefer AT, Monson CM. Combining cognitive-behavioral conjoint therapy for PTSD with 3, 4-methylenedioxymethamphetamine (MDMA): a case example. J Psychoact Drugs. 2019;51:166–73.

  6. 6.

    Sessa B, Higbed L, Nutt D. A review of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychiatry. 2019;10:138.

Download references

Author information



Corresponding author

Correspondence to Eric Vermetten.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vermetten, E., Yehuda, R. MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment. Neuropsychopharmacol. 45, 231–232 (2020).

Download citation

Further reading